Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome
Authors:
- 1 October 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 37 (5) , 498-504
Abstract
Purpose/Background: Antipsychotics are efficacious for tics and are increasingly prescribed to children with behavioral disorders. Antipsychotics have important adverse effects, and systematic monitoring of drug safety is infrequently performed. The objectives of this study were to determine the feasibility of antipsychotic safety monitoring in children with Tourette Syndrome using a defined protocol and to evaluate the risk of adverse effects with chronic use. Methods/Procedures: A prospective longitudinal study of children prescribed antipsychotics was performed. Children were monitored for extrapyramidal, metabolic, and hormonal adverse effects using the Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotic Medications guidelines. This included the measurement of height, weight, waist circumference, the Extrapyramidal Symptom Rating Scale, and laboratory tests of lipids, glucose, insulin, and prolactin at prespecified time points. Findings/Results: Fifty-seven children who started on risperidone or aripiprazole were monitored for a mean of 10 months 3 days. Significant increases in body mass index (BMI) and waist circumference percentiles occurred with time. There was a significant time by drug interaction, with children on aripiprazole having smaller changes in BMI initially, followed by a faster rate of increase than with risperidone. There was a significant difference between Extrapyramidal Symptom Rating Scale scores on versus before starting antipsychotics and significant increases in insulin and prolactin. Change from a healthy to overweight or obese BMI percentile occurred in 26%. Extrapyramidal symptoms occurred in 35%. Medication was discontinued because of metabolic effects in 19%, and extrapyramidal symptoms in 7%. Implications/Conclusions: Monitoring of antipsychotic safety in children is feasible and recommended to inform treatment decisions.Keywords
This publication has 23 references indexed in Scilit:
- Quetiapine use in adults in the community: a population-based study in Alberta, CanadaBMJ Open, 2016
- Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive studyCMAJ Open, 2014
- A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and AdolescentsThe Canadian Journal of Psychiatry, 2012
- Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: PharmacotherapyThe Canadian Journal of Psychiatry, 2012
- Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youthPaediatrics & Child Health, 2011
- Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youthPaediatrics & Child Health, 2011
- Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in ChildrenDrug Safety, 2011
- European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatmentEuropean Child & Adolescent Psychiatry, 2011
- Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary ReportPediatrics, 2007
- A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community PatientsSchizophrenia Bulletin, 2006